New GLP‑1‑adjacent supplement launched

Glucagon-like peptide-1 is a gut hormone that rises after meals and helps signal fullness. The Absorption Company has now launched WLP-1, a daily supplement it says supports that pathway without a prescription or injection. (nih.gov) (absorbmore.com) The product page says WLP-1 is an oral “GLP-1 biomimetic,” meaning a supplement meant to imitate some effects of the hormone system rather than deliver a drug like semaglutide. The company says it supports natural glucagon-like peptide-1 production, reduces the enzyme dipeptidyl peptidase-4 that breaks that hormone down, and also targets appetite and thermogenesis, or calorie burning at rest. (absorbmore.com 1) (absorbmore.com 2) The Absorption Company lists three branded ingredients behind those claims: IGOB131, CQR-300, and Capsifen. On its launch page, it cites results including 17.5% lower food intake and 27.4% greater fullness in one study, four pounds lost in four weeks in another, and up to 12% body-weight reduction in 10 weeks in a study of adults with body mass index above 26. (absorbmore.com 1) (absorbmore.com 2) The launch lands as glucagon-like peptide-1 drugs have reshaped the weight-loss market and pushed consumers toward adjacent products, from nutrition services to supplements. Business Insider reported this month that spending tied to glucagon-like peptide-1 use is spilling well beyond drugmakers. (businessinsider.com) (nih.gov) WLP-1 sits in a different regulatory lane from prescription obesity drugs. The Food and Drug Administration says dietary supplements can make structure-and-function claims about supporting the body, but they cannot legally claim to diagnose, treat, cure, or prevent disease, and labels must carry that disclaimer. (fda.gov) (ecfr.gov) That distinction matters for the evidence bar too. The Federal Trade Commission says health claims in advertising must be truthful, not misleading, and backed by competent and reliable scientific evidence. (ftc.gov) The company says directly that WLP-1 “does not contain semaglutide” and is “not intended to diagnose, treat, cure, or prevent any disease.” It is selling the supplement on its site for $99 as a one-time purchase or $69 a month on a subscription plan. (absorbmore.com 1) (absorbmore.com 2) The Absorption Company launched in 2024 and has been marketed around higher nutrient bioavailability, or the share of an ingredient the body can actually use. The brand was co-founded by Nikki Reed, Ian Somerhalder, Nate Medow, and Zeke Bronfman, and it rolled out a broader line of single-ingredient supplements in January 2026. (bevnet.com) (prnewswire.com) For shoppers, the pitch is simple: a capsule positioned near the glucagon-like peptide-1 boom, but sold as a supplement, not a medicine. What comes next is less about the launch itself than whether the company’s cited studies and marketing claims hold up under the same scrutiny now facing the wider weight-management category. (absorbmore.com) (ftc.gov)